Laura loves her diverse career Laura loves her diverse career Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
High Protein Diets for Cancer Patients High Protein Diets for Cancer Patients Learn more about the benefits of high protein diets for cancer patients from Taking Cancer On Through Flavour
Patient explains how IPF affects his life Patient explains how IPF affects his life A patient with moderate IPF explains how the disease affects his every day life. Learn more here.
Watercress Soup Video Watercress Soup Video This delicate soup is easy to eat with plenty of fragrant flavour. Click here to find out how to make it.
Honey and Cinnamon Cookies video Honey and Cinnamon Cookies video Find out how to make these simple and sweet honey and cinnamon cookies from Taking Cancer On Through Flavour
Carrot Cake Video Carrot Cake Video Find out how to make this moist and delicious carrot cake from Taking Cancer on Through Flavour at home
EMPERIAL-heart-failure-toplineresults EMPERIAL-heart-failure-toplineresults Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
The geography of pet parasites is changing The geography of pet parasites is changing Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
Transforming Cancer Care Transforming Cancer Care Transforming cancer care requires a diversity of minds.
emperor-preserved-heart-failure-full-data emperor-preserved-heart-failure-full-data Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Pioneering for progress in generalized pustular psoriasis Pioneering for progress in generalized pustular psoriasis An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
LastMile increases access to veterinary care in Africa LastMile increases access to veterinary care in Africa Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Agreement-to-acquire-NBE-Therapeutics Agreement-to-acquire-NBE-Therapeutics Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Niha Agarwalla Niha Agarwalla My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
What are acute exacerbations in IPF? What are acute exacerbations in IPF? Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Survey with Ipsos to gain insights human-animal bond Survey with Ipsos to gain insights human-animal bond Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Do we keep our promise? Do we keep our promise? Find out from a father-daughter duo how we live up to our new People Promise.
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
PRRS vaccine celebrates 25 years in Europe PRRS vaccine celebrates 25 years in Europe Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
Partnership canine oncology Partnership canine oncology The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.